A clinical Study to evaluate the safety and efficacy of Pankajakasthuri Breathe Eazy excel powder

A single arm clinical study to evaluate the efficacy of Pankajakasthuri Breathe Eazy excel powder in managing various respiratory Disorders - nil

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/04/065609

Enrollment

200

Registered

2024-04-12

Start date

Unknown

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J40-J47- Chronic lower respiratory diseases

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Age 18 Years and above Patients willing to take Breathe Eazy Excel Powder in a dose of 1 Tea spoon twice daily after food continuously for a minimum period of 3 months. Subjects willing to enroll in study by signing Informed consent. Subjects presenting with Allergic bronchitis, Allergic rhinitis, COPD, Sinusitis, Eosinophilia and other Respiratory tract infections.

Exclusion criteria

Exclusion criteria: 1 Patients allergic to the any of the ingredients of Breathe Eazy Excel Powder. 2. Pregnant and Lactating mother.

Design outcomes

Primary

Measure	Time frame
Any marked change in safety parameters measured during the administration of the product. • Reporting the effectiveness of this product in the management of Allergic bronchitis, Allergic rhinitis, COPD, Sinusitis, Eosinophilia and other Respiratory tract infections and associated complaints.Timepoint: 0th-baseline1st-first time blood investigations and 2nd-Blood investigations the end of the study.	—

Measure

Time frame

Any marked change in safety parameters measured during the administration of the product. • Reporting the effectiveness of this product in the management of Allergic bronchitis, Allergic rhinitis, COPD, Sinusitis, Eosinophilia and other Respiratory tract infections and associated complaints.Timepoint: 0th-baseline1st-first time blood investigations and 2nd-Blood investigations the end of the study.

—

Secondary

Measure	Time frame
Additional therapeutic advantages of the productTimepoint: 0th-baseline1st-first time blood investigations and 2nd-Blood investigations the end of the study.	—

Countries

India

Contacts

Public ContactShan Sasidharan

Pankajakasthuri Herbal Research Foundation

drshan@pkhil.com09188325339

Outcome results